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Abstract
Hyaluronic acid (HA) is a naturally occurring biodegradable polymer with a variety of
applications in medicine including scaffolding for tissue engineering, dermatological fillers, and
viscosupplementation for osteoarthritis treatment. HA is available in most connective tissues in
body fluids such as synovial fluid and the vitreous humor of the eye. HA is responsible for several
structural properties of tissues as a component of extracellular matrix (ECM) and is involved in
cellular signaling. Degradation of HA is a step-wise process that can occur via enzymatic or non-
enzymatic reactions. A reduction in HA mass or molecular weight via degradation or slowing of
synthesis affects physical and chemical properties such as tissue volume, viscosity, and elasticity.
This review addresses the distribution, turnover, and tissue-specific properties of HA. This
information is used as context for considering recent products and strategies for modifying the
viscoelastic properties of HA in tissue engineering, as a dermal filler, and in osteoarthritis
treatment.
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1. Introduction to hyaluronic acid
Hyaluronic acid (HA), also named hyaluronan, is a high molecular weight (105–107 Da)
naturally occurring biodegradable polymer. HA is an unbranched non-sulfated
glycosaminoglycan (GAG) composed of repeating disaccharides (β-1,4-D-glucuronic acid
(known as uronic acid) and β-1,3-N-acetyl-D-glucosamide) (Figure 1) [1–3]. HA can
include several thousand sugar molecules in the backbone. HA is a polyanion that can self-
associate and that can also bind to water molecules (when not bound to other molecules)
giving it a stiff, viscous quality similar to gelatin [4].
Hyaluronic acid is one of the major elements in the extracellular matrix (ECM) of vertebrate
tissues. It is available in almost all body fluids and tissues, such as the synovial fluid, the
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vitreous humor of the eye, and hyaline cartilage (Table 1) [5–8]. This biopolymer functions
as a scaffold, binding other matrix molecules including aggrecan [2]. It is also involved in
several important biological functions, such as regulation of cell adhesion and cell motility,
manipulation of cell differentiation and proliferation, and providing mechanical properties to
tissues [6]. Several cell surface receptors such as CD44, RHAMM, and ICAM-1 have been
shown to interact with HA influencing cellular processes including morphogenesis, wound
repair, inflammation, and metastasis [9–12]. Moreover, HA is responsible for providing the
viscoelasticity of some biological fluids (synovial fluid and vitreous humor of the eye) and
controlling tissue hydration and water transport (Table 1) [4]. In addition, HA has been
found during embryonic development in the umbilical cord, suggesting materials composed
of HA may persuade favorable conditions for tissue regeneration and growth [13–17].
HA's characteristics including its consistency, biocompatibility, and hydrophilicity have
made it an excellent moisturizer in cosmetic dermatology and skin-care products [4].
Moreover, its unique viscoelasticity and limited immunogenicity have led to its use in
several biomedical applications such as viscosupplementation in osteoarthritis treatment, as
an aid in eye surgery, and for wound regeneration [4, 5]. In addition, HA has currently been
explored as a drug delivery agent for different routes such as nasal, oral, pulmonary,
ophthalmic, topical, and parenteral [4, 18–22].
2. History of hyaluronic acid
In 1934, Karl Meyer and his colleague John Palmer were the first investigators who
discovered and isolated HA from the vitreous body of cows' eyes [2, 4]. In the 1950s, the
chemical structure of HA was solved by this group. They found that HA is composed of two
sugar molecules (D-glucuronic acid (known as uronic acid) and D-N-acetyl glucosamine)
and called it hyaluronic acid (hyaluronan). This name is derived from “hyalos” (the Greek
word for glass + uronic acid). Initially, they isolated HA as an acid but it behaved like a salt
in physiological conditions (sodium hyaluronate) [2, 4, 5]. Several years after them in 1942,
Ender Balazs patented the first application of HA as a substitute for egg white in bakery
products [4].
The first biomedical application of HA took place in late 1950s when HA was used for a
vitreous substitution/replacement during eye surgery. For medical applications, HA was
initially isolated from umbilical cords and shortly afterward, from rooster combs [4, 5].
Later on, HA was isolated from other sources and the structural/biological characteristics of
this polysaccharide were investigated more deeply in several laboratories [4].
3. Properties of hyaluronic acid
3.1. Chemical properties of hyaluronic acid
Structural studies showed that the two sugar molecules, D-glucuronic acid and D-N-acetyl
glucosamine, in the HA disaccharide structure are connected together through alternative
β-1,4 and β-1,3 glycosidic bonds (Figure 1) [2, 4]. The hyaluronic acid backbone is stiffened
in physiological solution via a combination of internal hydrogen bonds, interactions with
solvents, and the chemical structure of the disaccharide. HA molecular investigations
suggested that the axial hydrogen atoms form a non-polar face (relatively hydrophobic) and
the equatorial side chains form a more polar face (hydrophilic) which led to a twisted ribbon
structure for HA called a coiled structure [4].
HA's structural characteristics hinge on this random coiled structure in solution. At very low
concentrations, chains entangle each other, leading to a mild viscosity (molecular weight
dependent). On the other hand, HA solutions at higher concentrations have a higher than
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expected viscosity due to greater HA chain entanglement that is shear-dependent. For
instance, a 1% solution of high molecular weight HA (Mw > ~1000 kDa) can behave like
jelly, but when shear stress is applied it will easily shear thin and can be injected via a thin
needle [4]. As such, HA is known as a “pseudo-plastic” material. This rheological property
(concentration and molecular weight dependent) of HA solutions has made HA ideal for
lubrication in biomedical applications [4].
In addition to the unique viscosity of HA, the viscoelasticity of HA is another characteristic
resulting from entanglement and self-association of HA random coils in solution [2]. It was
suggested that the molecular self-association of HA occurs by forming anti-parallel double
helices, bundles and ropes. Further experiments verified that HA chain-chain association
indeed occurred in solution. Moreover, studies proposed that hydrogen bonding between
adjacent saccharides occurred alongside mutual electrostatic repulsion between carboxyl
groups, thus stiffening HA networks [4, 7, 23]. Viscoelasticity of HA can be tied to these
molecular interactions which are also dependent on concentration and molecular weight.
Electrostatic and ionic effects on HA have also been evaluated as a function of counter-ion
type and valency. Studies suggested that these greatly affect rheological and hydrodynamic
properties of HA. In one study, the effect of electrostatic and ionic interactions was
investigated by comparing HA solution properties in deionized water (D.I.), 0.5 M NaCl,
and 0.5 M NaOH. The role of hydrogen bonds was investigated by comparing
concentration-dependent solution properties. This revealed the effect of electrostatic
shielding and also the profound effect of alkaline pH on HA chain stiffness. The study also
showed that solution properties affect the hydrogen bonding and electrostatic interaction
between the solution and HA resulting in a change in HA chain stiffness [2, 24]. Moreover,
the hydrodynamic radius of HA was found to be greater in D.I. water than in 0.5 M NaCl or
0.5 M NaOH (D.I. water > 0.5M NaCl > 0.5M NaOH). The high pH shrank the volume
occupied by HA (i.e. the apparent size of the polymer chains). The volume occupied by HA
chains was decreased by more than 100 times when changing from D.I. water to 0.5 M
NaOH. This dramatic change was attributed to increased electrostatic interactions and
hydrogen bond formation resulting in the reduction of the hydrodynamic radius of HA [2].
3.2. Biological properties of hyaluronic acid
As mentioned before, hyaluronic acid performs several structural tasks in the extracellular
matrix (ECM) as it binds with cells and other biological components through specific and
non-specific interactions. Several extracellular matrix proteins are stabilized upon binding to
HA. Specific molecules and receptors that interact with HA are involved in cellular signal
transduction; molecules such as aggrecan, versican, and neurocan, and receptors including
CD44, RHAMM, TSG6, GHAP, ICAM-1 and LYVE-1 are examples of cell components
that bind to HA [4]. Between these receptors, CD44 (cell surface glycoprotein) and
RHAMM (receptor for HA-mediated motility) seem to have received more attention since
they have been found to be involved in cancer metastases [25–27]. CD44 is a structurally
variable and multifunctional cell surface glycoprotein on most cell types and is perhaps the
best characterized transmembrane HA receptor so far. Due to its wide distribution and based
on current knowledge, CD44 is currently considered to be the primary HA receptor on most
cell types [28].
New receptors for HA have been identified recently and the function of some HA receptors
have recently been described. RHAMM has been found on surface of the cells, as well as in
the cytosol and nucleus. It regulates cellular responses to growth factors and plays a role in
cell migration, particularly for fibroblasts and smooth cells [4, 29, 30]. TSG6, a 35 kDa
glycoprotein with a link module in the N-terminus, has also been reported to bind with HA
[31]. GHAP (glial hyaluronate-binding protein) is a naturally occurring versican degradation
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product which forms a fine net surrounding myelinated optic nerve axons, although no or
only faint staining of GHAP is noticed in the optic nerve head. GHAP could also bind to
HA. It one study, HA and GHAP vanished from optic chiasm and contralateral optic nerves
treated with hyaluronidase [32, 33].
ICAM-1 (intracellular adhesion molecule-1) has been reported as an active cell surface
receptor for HA. According to the literature, this protein is responsible for removing HA
from lymph and blood plasma, which likely encompasses most of the HA turnover. HA
binds to ICAM-1 expressed on lymphocytes and endothelial cells [34]. In the urothelium,
HA inhibits adherence of immune complexes to polymorphonuclear cells [34]. It also
prevents leukocyte migration and aggregation[34]. Another study showed that binding HA
to ICAM-1 does not induce endocytosis, which further complicates the role of ICAM-1 as a
receptor for HA [35].
LYVE-1 (lymphatic vessel endothelial HA receptor) is related close to CD44. LYVE-1 is
preferentially available on lymphatic endothelial cells that do not express CD44 [36]. In
addition, LYVE-1 is available in the sinusoidal endothelium of liver and spleen and is
expressed in discrete populations of activated macrophages. It has been shown that HA
endocytosis is mediated by LYVE-1 in transfected fibroblasts [37–39]. It is also shown that
LYVE-1 has a significant regulatory function in the catabolism of HA in the aforementioned
organs and a role in HA signaling or cellular migration and differentiation [2, 38].
Toll-like receptors (TLRs) are a group of receptors which are members of the interleukin-1
receptor family. TLR-4 is widely available in tissues, including liver, brain, heart, and
kidney [40, 41]. TLRs work as activator for monocytes, macrophages and dendritic cells,
and therefore act as initiator for defending against bacterial infection [42–45]. Tetra and
hexasaccharides (low molecular weight HA) but not intermediate or high molecular weight
HA (80,000–600,000 kDa) binds to TLR-4 (e.g. mature dendritic cells) [46]. Upon
inflammation and tissue injury, high molecular weight HA in extracellular matrix is broken
down into lower molecular weight HA fragments, which can activate an innate immune
response. This activation was reported to result from the binding of low molecular weight
HA fragments to TLR-2 and/or TLR-4 receptors [47, 48].
Hyaluronic acid also stimulates gene expression in macrophages, endothelial cells,
eosinophils, and certain epithelial cells. High molecular weight HA does not seem to be
involved in gene expression and only low/intermediate molecular weight HA
(2×104−4.5×105 Da) is known to promote gene expression [4, 46, 49]. As an example, HA
is known to have an important role in wound healing and scar formation. Products of HA
degradation (low molecular weight HA) were found to contribute to the scar formation
process. Moreover, scar formation was minimized when high molecular weight HA was
found in wound fluid during fetal wound healing. These results suggested that the molecular
weight of HA plays a significant role in wound healing and scar formation. The findings
also suggested that high molecular weight HA favored cell quiescence and supported tissue
integrity, whereas production of HA fragments signaled injury and initiated the
inflammatory response [2, 4, 50].
HA can be a key player in the activation or suppression of inflammation. Over the early
steps of inflammation, HA participates in the improvement of cell infiltration [51]. It
facilitates an increase in pro-inflammatory cytokines TNF-α, IL-1b and IL-8 through a
CD44-mediated mechanism [52]. The inflammatory response can also be propagated by
releasing TSG-6, an HA binding protein, which is simulated by TNF-α [53, 54]. HA also
affects the adhesion of cytokine-activated lymphocytes to the endothelium [55]. The free
radical scavenging and antioxidant characteristics of HA influence suppression of the
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inflammatory response [46, 56]. In addition, HA may also operate as a negative feedback
loop in inflammatory activation.
Cell proliferation is an important phase of the tissue repair process after damage (e.g. by
inflammation) [54]. HA is necessary for fibroblast detachment from the extracellular matrix
and mitosis [57, 58]. HA has a mitogenic influence directly on cells however the relief of
detachment permits mitosis to take place and therefore HA has a function in cell
proliferation indirectly [59]. In the early stages of wound repair when increased HA
synthesis takes place, cell migration is promoted [60–64]. The newly deposited ECM rich in
HA provides an open, hydrated environment that aids cell migration via CD44 and
RHAMM [2, 65–69].
The key element of wound repair is angiogenesis. The angiogenic characteristics of low
molecular weight HA oligosaccharides have been explained in detail elsewhere [2, 46, 70–
78]. When ECM forms, the peripheral keratinocytes undergo an increase in mitosis and
proliferation before migration across the new matrix. The matrix, rich in HA, supports and
develops the proliferating basal keratinocytes and aids their movement via a CD44-mediated
mechanism [79–83]. After re-epithelialization has taken place, remodeling occurs for the
new matrix [84]. The remodeling process can lead to scarring. Matrix rich in HA observed
in fetal wounds suggests that HA may decrease collagen deposition, thereby improving
remodeling and decreasing scarring [2, 85, 86].
4. Synthesis of hyaluronic acid
Hyaluronic acid is a natural polymer biologically synthesized by cells in the body via an
enzymatic process. HA production is a unique, highly controlled, and continuous process,
HA is produced and secreted by cells including fibroblasts, keratinocytes, or chondrocytes.
The Golgi network is the production site for most glycosaminoglycans. In tissues such as
skin and cartilage where HA comprises a large portion of the tissue mass, the level of HA
synthesis is very high. HA is naturally synthesized by hyaluronan synthases (HAS1, HAS2,
and HAS3), a class of integral membrane proteins [4, 87, 88]. In HA production by
hyaluronan synthase enzymes, large linear polymers of the repeating disaccharide units are
made. The mechanism of HA synthesis involves chain extension by addition of a
monosaccharide (alternating addition of glucuronic acid and N-acetyl glucosamine) to the
reducing end of the chain [2, 4, 10]. The number of repeat disaccharides in a completed HA
molecule can reach as high as 10,000 or more and a molecular weight of around 4 million
Daltons (molecular weight of each disaccharide is about 400 Daltons). Since the average
length of a disaccharide is about 1 nm, a HA molecule of 10,000 repeats could extend 10
μm if stretched from end to end (approximately equal to the diameter of a human
erythrocyte) [4, 10, 89, 90].
5. Degradation of hyaluronic acid
Degradation of HA is a step-wise process that can occur via enzymatic or non-enzymatic
reactions. Three types of enzymes (hyaluronidase, β-D-glucuronidase, and β-N-acetyl-
hexosaminidase) are involved in enzymatic degradation of hyaluronic acid. These enzymes
are found in various forms, in the intercellular space and in serum. Hyaluronidase cleaves
high molecular weight HA into smaller fragments while the other two enzymes degrade the
fragments by removing non-reducing terminal sugars [4, 91, 92]. It was observed that
cleavage can occur in a single glycosidic bond on the HA backbone causing fragmentation
or the enzyme can remove a single monosaccharide unit from the HA backbone [91].
Enzymes not only help to degrade HA but also play an important role defining HA. For
instance, enzymes available in the cytosol of cells are involved in the trimming of
oligosaccharides [91].
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Non-enzymatic mechanisms of HA degradation include thermal or shear stress.
Ultrasonication degrades HA in a non-random fashion. Studies suggested that high
molecular weight HA chains degraded slower than low molecular weight HA chains
subjected to ultrasonication [2, 91]. Heat is another type of stress leading to HA degradation.
Rheological studies on HA solutions showed that increasing temperature resulted in
degradation and decreased viscosity exponentially as a function of temperature [91].
In addition, chemical reactions such as acidic/alkaline hydrolysis and degradation by
oxidants are categorized as non-enzymatic degradation pathways for HA [91–93]. These
types of degradation occur in a random fashion often resulting in disaccharide fragment
production. Acidic hydrolysis degrades the glucuronic acid moiety. On the other hand,
alkaline hydrolysis occurs on N-acetylglucosamine units [91]. HA can also degrade via
oxidation. Reactive oxygen species (ROS) can be generated from cells as a consequence of
aerobic respiration. Superoxide anions, hydroxyl radicals, and hypochloride are examples of
species that cause HA chain cleavage. ROS are proposed to be involved in several
inflammatory and degenerative processes such as arthritis but their mechanism of action in
the disease are myriad and still largely defined [2, 91].
6. Turnover and possible pathways for elimination of hyaluronic acid
Studies showed that the concentration of HA in the human body varies from a high
concentration of 4 g/kg in umbilical cord, 2–4 g/L in synovial fluid, 0.2 g/kg in dermis, and
about 10 mg/L in thoracic lymph, to a low concentration of 0.1–0.01 mg/L in normal serum.
In an average human body (70 kg), the total HA content is approximately 15 g [2, 4]. From
this 15 g, the largest amount was found in the extracellular matrix (ECM) of skin and
musculoskeletal tissue. Depending on the location in the body, most of the HA is
catabolized within days. Studies indicated that the normal half-life of HA varied from 1–3
weeks in inert tissues such as cartilage to 1–2 days in the epidermis of skin. The half-life in
blood was much shorter (2–5 minutes). Besides the enzymatic degradation and non-
enzymatic degradation pathways described previously, two more pathways are engaged in
HA catabolism: turnover (internalization and degradation within tissue) and release from the
tissue matrix, drainage into the vasculature, and clearance via lymph nodes, liver, and
kidney (Figure 2) [2].
In structural tissues like bone or cartilage with no or little lymphatic drainage, HA
degradation occurs in situ with other ECM molecules such as collagens and proteoglycans.
On the other hand, in skin and joints, a minimal fraction (approximately 20–30%) of HA
degrades in situ. Approximately, 50% of HA in the body is available in skin tissue. Since
HA is restricted to the small intracellular space of skin tissue, its half-life is a bit longer at
days to weeks [2, 92]. Usually, the HYAL enzymes (hyaluronidases) are assumed to be the
predominant catabolic mechanism involved in this process throughout the vertebrate body.
However, HA catabolism can take place by either enzymatic degradation or scission by
reactive oxygen species (ROS). Both mechanisms take place at the same time, but the
relative contribution is unclear [92].
Hyaluronidases are an enzyme protein family with a high degree of sequence homology.
There are six genes tightly clustered at two chromosomal locations. Three genes encode for
HYAL1, HYAL2, and HYAL3 hyaloronidases. HYAL1 and HYAL2 form the major
hyadonidases of somatic tissues. HYAL2, which is fixed to plasma membrane, cleaves high
molecular weight HA to a product of approximately 20 kDa. HYAL1 seems to be a
lysosomal enzyme, cleaving HA mainly into tetrasaccharides. HYAL3 is broadly expressed
however its function is not well understood. Three additional genes encode for HYAL4,
PHYAL1 (pseudogene HYAL1), and SPAM1 (Sperm Adhesion Molecule-1)
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hyaluronidases. The mechanisms of action for these three hyaluronidases are still unknown
[94].
HA can also be eliminated through the lymphatic system draining the extracellular space of
relatively dense tissues. First, high molecular weight HA is partially degraded before it
releases from the tissue matrix. Upon release from the tissue matrix, degraded HA enters the
lymphatic system. HA metabolic degradation mostly takes place in the lymphatic system as
HA drains through peripheral tissues to the blood circulation [2]. One of the functions of the
lymphatic system is to collect filtered plasma and interstitial fluid and transport them back to
the blood circulation. Studies showed that most of the subcutaneously injected radio-labeled
HA is picked up and degraded in lymphatic tissue [2, 92]. Remaining HA enters into the
blood circulation and is rapidly removed in the liver by sinusoidal endothelial cells or
eliminated via kidneys. In the blood circulation, the liver eliminates about 80% of HA and
kidneys clear 10% of HA from bloodstream (Figure 2). As mentioned before, the daily
turnover of HA is on the order of one-third (5 g) of the total HA body content (15 g) [2].
Synovial fluid is one of the body fluids containing high molecular weight HA. Lubrication
and viscoelasticity are provided by the high molecular weight HA in synovial fluid. In a
healthy joint, high levels (2–4 g/L) of HA with high molecular weight (approximately 6–7
MDa) are required for synovial fluid to function properly. In order to maintain synovial fluid
lubrication and viscoelasticity, macromolecules including HA are continuously secreted by
synoviocytes into the synovial fluid. Every time pressure is increased, fluid is pushed out of
the joint cavity into micro-capillaries embedded in the synovium. Therefore, HA escapes
through the interstitial drainage pores in the synovial lining (diameter 30–90 nm). It is also
suggested that high molecular weight HA can form a layer at the tissue-fluid interface
forming a “shell” that is not drained into micro-capillaries. The normal intra-articular
turnover time for HA was found to be less than 40 hours. Studies showed that both HA
molecular weight and concentration are decreased in patients with arthritis resulting in a
significant reduction in synovial fluid functionality. Moreover, studies showed that
production and secretion of ROS in arthritic joints degraded the HA in synovial fluid and
cartilage [2, 4, 95–97].
7. Biomedical application of hyaluronic acid
7.1. Application of hyaluronic acid in tissue engineering
Since hyaluronic acid is one of the main components of body tissues, its potential for tissue
engineering applications has been highly touted. HA is highly soluble at room temperature
and has a high rate of elimination and turnover depending on its molecular weight and
location in the body. Each of these properties could be a barrier for HA scaffold fabrication
and structural integrity. To overcome these limitations, modification and crosslinking of
hyaluronic acid have been proposed [5, 98, 99]. To chemically modify HA, thee functional
groups of HA (the carboxylic acid, the primary and secondary hydroxyl groups, and the N-
acetyl group) have been targeted. All of these HA modifications have been divided into two
categories: “monolithic” and “living” [18]. Monolithic terminally-modified HA derivatives
cannot be used for crosslinking in the presence of live cells or tissues. Living HA
derivatives, however, can be used for crosslinking and covalent bond formation in the
presence of cells. Living HA derivatives are needed in most cases for clinical and preclinical
applications in 3D cell cultures and cell delivery in vivo. This topic has been thoroughly
addressed elsewhere [18], but key highlights are offered below.
Currently, water-soluble carbodiimide crosslinking [100], polyvalent hyadrazide
crosslinking [101], divinyl sulfone crosslinking [102], disulfide crosslinking [56], and
photocrosslinking of hydrogels through glycidyl methacrylate-HA conjugation [103] have
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been introduced for tissue engineering applications of HA. Chemical crosslinking of HA
combines desirable biological and mechanical properties, even for bone or cartilage tissue
engineering [5, 98]. Moreover, crosslinking extends the HA degradation process in vivo and
provides long-term stability. Crosslinking HA at various densities has been used for multiple
applications including orthopedics, cardiovascular medicine, and dermatology [98].
Common functional groups used for radical polymerization are acrylates and methacrylates
because these functional groups immediately react with radicals generated during
photopolymerization. Carboxyls on the HA backbone are functional groups often used for
modifications to introduce methacrylates. The reaction of glycidyl methacrylate with HA to
create GMHA conjugates is another approach for HA functionalization and
photocrosslinking. Crosslinking of GMHA macromers into hydrogels facilitated the
production of a range of degradation and material characteristics [18, 103].
Photocrosslinking produced dense and strong gels. In addition, a range of complex fluids
(microgels) were developed using low degrees of crosslinking. GMHA hydrogels were also
copolymerized with acrylated versions of poly(ethylene glycol) (PEG) and PEG-peptide
macromers [104]. Moreover, IPNs of the GMHA and N-dimethylacrylamide have also been
produced to develop high moduli hydrogels. These gels were shown to be biocompatible,
however, encapsulation in these high modulus gels has not been achieved before [18, 105–
107]. Photopolymerization has also been performed by grafting poly(2-hydroxyethyl
methacrylate) or cinnamic acid to HA [18, 108, 109].
Photocrosslinked HA hydrogels have been shown to be used for different applications
including cartilage tissue engineering, cardiac repair, molecule delivery, valvular
engineering, control of stem cell behavior, and microdevices [18]. Studies have suggested
positive results for cell growth on photocrosslinked HA networks incorporated with
chondrocytes. Chondrocytes within the HA hydrogel retained viability and were able to
generate cartilage within the porous network [98, 110]. This type of photopolymerization
has also been used in heart valve applications to mimic cardiac valve development [25]. In
another study, IPNs of collagen within an HA hydrogel were developed with advantages of
both mechanical stability of photocrosslinked HA networks and cellular adhesion to
collagen [18, 111].
Several studies have reported the encapsulation of mesenchymal stem cells (MSCs) or
chondrocytes into this type of HA hydrogels to regenerate damaged cartilage tissue. A novel
study extended the advantage of redox-initiated HA hydrogels to cardiac repair [112].
Photocrosslinked HA is also being studied for valvular engineering due to the presence of
HA within the structure of the native valve. Studies showed that valvular interstitial cells
(VICs) are not easy to culture in ordinary culture mediums with peptide- and protein-
modified surfaces but these cells adhered to and proliferated on HA hydrogels [18, 113].
Moreover, photocrosslinked HA was suggested for use in 3D stem cell encapsulation to
regulate the differentiation of trapped stem cells. For example, HA hydrogels have been
introduced into microbioreactor systems which allow for the 3D cultivation of hESCs [18,
114].
HA has also been combined with other polymers such as polypyrrole to develop
multifunctional copolymers. HA functionalized with polypyrrole is electronically conductive
and supports cell growth. This copolymer could offer unique properties for tissue
engineering applications [115, 116]. In one study, N -(1-aminoprop-3-yl) pyrrole was
conjugated with HA using carbodiimide chemistry. Then, PyHA was electrochemically
polymerized to form a stable, biocompatible 20–40 nm HA coating on conducting polymer
substrates including indium tin oxide, platinum, and polystyrene sulfonate-doped
polypyrrole surfaces. These covered surfaces were hydrophilic and resistant to fibroblast and
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astrocyte attachment. The immobilized HA films were stable under physiological conditions
for three months [18, 117].
Benzyl derivatives of HA are another category of polymeric scaffolds used for tissue
engineering of cartilage to modulate degradation rates. Studies on these derivatives
suggested the potential of benzyl esters of HA as a scaffold for chondrocytes in cartilage
tissue engineering. These scaffolds are hydrophobic and degrade at predictable rates. In an
early study, implanting one of these cell-seeded scaffolds in mice showed development of
cartilage. In a recent human clinical study, the benzyl HA scaffold was used for cartilage
regeneration. After implantation of the scaffold, the graft had integrated with surrounding
cartilage and developed “normal”-looking tissue in the damaged area. Another study showed
evidence of chondrocyte differentiation, collagen type II and aggrecan production, and an
overall down regulation of collagen type I using this type of scaffold. Similar studies
conducted with rat mesenchymal stem cells (MSCs) loaded into benzyl HA grafts suggested
that the implants exhibited properties conducive to both chondrocyte differentiation as well
as the formation of fibrocartilaginous tissue in vivo [98, 118].
Since HA is a biocompatible natural polymer, development of scaffolds based on HA
appears to be suitable for surfaces contacting blood. For example, HA crosslinked with
divinyl sulfone (DVS) in the presence of ultraviolet light has been suggested as a “non-
activating” surface for cell adhesion in heart valve tissue engineering. In one study a DVS-
crosslinked HA scaffold was seeded with smooth muscle cells. This research showed that
smooth muscle cells increased the synthesis of elastin and collagen, essential components of
aortic valve tissues, compared to cells cultured on plastic culture plates [88, 98, 119].
To synthesize artificial extracellular matrices (ECMs) for regenerative medicine
applications, modification of glycosaminoglycans (GAGs) including HA has also been
reported [18]. For this purpose, thiol modification of the HA carboxylate groups has been
reported in a research study. Thiol-modified HA forms a biocompatible hydrogel
spontaneously via self-crosslinking when exposed to the air. Crosslinking with difunctional
electrophiles is possible in the presence or absence of cells [18, 120, 121]. The first
preclinical application of crosslinked thiolated HA and gelatin was explored for
mesenchymal stem cell delivery to full-thickness defects in the patellar groove of rabbit
femoral articular cartilage. The defects totally healed after 12 weeks [18]. In another study,
HA was modified via bromoacetate (haloacetate-modified HA) to form a hydrogel. Similar
to thiol-modified HA, this modification resulted in a biocompatible hydrogel that could be
used for tissue regeneration. Cells failed to proliferate on the scaffold unless gelatin was
added, suggesting attachment and visibility on the gelatin-containing scaffolds [18, 122].
Hydrazide modification using adipic dihydrazide has also been employed to develop HA
derivatives. Dihyadrazide-modified HA are able to form hydrazine linkages with ketones
and aldehydes as well as acylhydrazides with acylating agents, thus allowing crosslinking
and hydrogel formation or conjugation of drugs or polypeptides to HA backbone [18, 123].
Other techniques including tyramine modification of HA, aldehyde modification of HA, and
huisgen cycloaddition (click chemistry) have also been introduced to produce HA hydrogels
for cell delivery and to simulate ECM in regenerative medicine [18, 124–126].
Auto-crosslinked and in situ crosslinked HA hydrogels are another category of crosslinking
used for tissue engineering. The requirement for surgical implantation is the major limitation
of most scaffolds used for tissue engineering. Application of HA that crosslinks after
injection has been introduced for three main reasons. First, the injectable HA could be filled
into defects of any shape and crosslinked in situ. Second, crosslinkable HA may adhere to
the native tissue resulting in mechanical or chemical interlocking and a cohesive scaffold-
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tissue interface. Third, injection and laparoscopic methods can be used to reduce the
invasiveness of the surgical procedure [127]. Studies showed that HA crosslinked using
adipic acid dihydrazide and aldehyde chemistry could form a flexible hydrogel in situ upon
mixing [128]. In another study, poly(lactic-coglycolic acid) nanoparticles were mixed with
HA of similar chemistry to develop an in situ crosslinkable system with drug delivery
potential. Although such in situ crosslinking has been shown to form flexible hydrogels with
reasonable mechanical properties, potential cytotoxicity of the reactions used in these
techniques are still an important issue to consider [129].
In all of the described techniques, chemical reactions have been used to either modify the
HA backbone or to crosslink HA for hydrogel formation. In most cases, the proposed
crosslinking chemical reaction and/or reagents used have still shown cytotoxicity. In the
case of HA backbone functionalization, pre-crosslinking modifications require an additional
step to hydrogel formation which can make the overall scaffold fabrication more complex.
Therefore, there is a demand for in situ crosslinking strategies to develop simple techniques
free of chemical reactions for HA based scaffold fabrication with low or no toxicity issues.
7.2. Application of hyaluronic acid as a dermal filler
The influence of sun exposure, gravity, and years of facial muscle movements starts to
appear as wrinkles on the skin. During the aging process, basic changes in the skin, soft
tissue, and skeletal support of the face occur resulting in a breakdown of the tissues under
the skin leaving lines or other facial defects [130, 131]. Skin aging can be divided in two
categories: internal aging and external aging.
Internal aging of skin causes various histological changes in different skin layers such as
flattening of the epidermal-dermal interface, a decrease in the number of melanocytes and
Langerhans cells in the epidermis, a loss of dermal papillae, dermal atrophy, a decrease in
the number of mast cells, fibroblasts, and blood vessels, a loss of elastic tissue in the fine
subepidermal elaunin network, and abnormal thickening and fragmentation of elastic tissue
in the reticular dermis [131]. Internal aging also reduces several skin functions such as type I
and type III collagen production, the epidermal turnover rate, and melanocyte activity [131,
132].
External aging is influenced by sun exposure and UV radiation and also causes histological
changes which are different from some of the changes caused by internal aging. External
aging is typified by damage of elastic tissue and decrease in cellularity. Photodamage
induces elastosis, the overgrowth of abnormal elastic fibers, and an increase in population of
histiocytes, fibroblasts, and mast cells [131, 132]. In both internal and external aging,
collagen content and melanocyte activity are decreased and wound healing is abnormal
[131].
To address age-related changes in skin quality and appearance, several treatments have been
proposed (Table 2). Development of soft-tissue fillers (dermal fillers) can help lines and
wrinkles to be filled temporarily (or `permanently') [130]. It seems an ideal dermal filler
should be temporary but long-lasting (months to a year or longer), having minimum side
effects and no allergenic effect, easy to administer, having minimum pain or no pain upon
injection, and a reasonable cost for both the physician and the patient [130]. Depending on
the residence time in tissue, dermal fillers are categorized as temporary, semipermanent (at
least 18 months), and permanent. They are also classified based on their composition with
primary ingredients such as collagen (bovine, porcine, or human), animal or synthetic
hyaluronic acid, poly-L-lactic acid, calcium hydroxyapatite, polymethyl methacrylate, and
polyacrylamide gel (Table 3) [3, 131, 133, 134].
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Hyaluronic acid has been approved by the Food and Drug Administration (FDA) as a dermal
filler. In 2006, cosmetic injections of HA were known to be the second most popular non-
surgical procedure for women and the third most popular procedure for men [135–138]. HA
has a very short half-life and, therefore, is chemically crosslinked to extend duration as a
dermal filler [139]. HA is not involved in the structure of collagen and does not enhance the
shortage of HA in aged skin, but simply works by augmenting volume [130, 135].
A set of chemical modifications are required to apply to HA as a dermal filler. HA employed
to make dermal fillers is usually provided to the manufacturer in a dry powder form.
Combining this powder with water forms a viscous solution of HA. This solution is known
as free HA, which is uncrosslinked and unmodified. If this product was to be used as a
dermal filler, it would be rapidly eliminated from the injection site by drainage or
degradation pathways (less than a week). To overcome the lack of residence of HA
solutions, dermal fillers were developed using crosslinked HA. The crosslinking creates a
polymer network, transforming a viscous solution to a weak gel. HA gel imparts a physical
and chemical barrier to deter drainage or degradation. Therefore, residence time increases by
crosslinking HA [130].
The two crosslinkers employed in HA dermal fillers currently on the US market are 1,4-
butanediol diglycidal ether (BDDE), and divinyl sulfone (DVS). Both of them react to
hydroxyl groups on HA chains and give similar outcomes; slowing down the drainage and
degradation of dermal fillers injected into the skin [130]. In the US, collagen-based fillers
were used by physicians for the treatment of lines and wrinkles through the 1980s and the
1990s. In Europe, however, dermal fillers were developed that would soon influence the
majority of US doctors to use fillers for their patents. This revolution started with the
development of HA fillers [136].
Since its launch in Europe in 1996, HA has become the “gold standard” in fillers for treating
wrinkles, hydrating skin, and increasing volume [3]. Many dermal fillers have been
developed since that time. Restylane®, Perlane® (FDA approved), and Sub-Q® (not FDA
approved) from Q-Med AB (Upsala, Sweden) is made from HA beads within a solution of
HA. Hylaform®,Captique™, Juvéderm™ (FDA approved), Surgiderm® (not FDA
approved), and Voluma® (not FDA approved) from Allergan (Irvine, CA, USA) are
produced from crosslinked HA in a single state (no beads) (See Table 3 for more HA dermal
fillers) [3].
In the US, Hylaform ® was the first HA-based filler available for use. This product was
developed by Genzyme Biosurgery (New Jersey, US) and was marketed by Inamed® (Santa
Barbara, CA, US) before acquisition by Allergan, Inc. (Irvine, CA, US) in 2006. Hylaform®
is a sterile, colorless gel material in which HA is crosslinked with divinyl sulfone. It is FDA
approved (April, 2004) and derived from an avian source (rooster comb). The HA is 20%
crosslinked (4.5–6.0 mg/ml) with a particle size of ~500 μm. The main disadvantage of this
product is longevity, as most would report that the benefits generally last for 3–4 months
[136]. Captique™ is the second FDA-approved (December 2009) HA filler developed by
Genzyme/Inamed/Allergan; now Mentor Corporation (Santa Barbara, CA, US). Capitique™
was manufactured based on Genzyme's patented non-animal stabilized HA technology. This
prevented the possibility of immunological issues related to the previous avian source HA
based dermal fillers such as Hyaform®. Again, the HA is 20% crosslinked by divinyl
sulfone (4.5–6.0 mg/ml) and gel particle size of ~500 μm. Captique™ was also shown to
have treatment duration anywhere between 3 to 6 months [136].
The next HA-based dermal filler approved by FDA in the US was Restylane® (December,
2003). It is a non-animal HA derivative made from fermentation of equine streptococci and
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crosslinked with 1,4-butandiol diglycidylether (BDDA). The HA (20 mg/ml) is only lightly
crosslinked (1%) with a particle size of ~400 μm. Restylane® has lower degree of
crosslinking with different crosslinking chemistry, higher HA concentration, and smaller
particle size comparing to previous products. The FDA approved this product for mid-
dermal applications including deep wrinkle correction, lip augmentation, nasolabial fold
correction, and for glabellar creases. The application of Restylane® in clinical trials dates
back to the 1990s. In two European clinical trials by Duranti et al. and Olenius (both in
1998), the duration of effect was found to be ~8 months. Restylane® has been employed for
the past several years by numerous doctors with acceptable results (~6 to 12 months). It was
reported that Restylane® can be injected easily with small-gauge needles such as gauge 30.
The major concern for Restylane® injection is mild reaction at the site of injection and pain
during the injection [136]. Juvéderm™ is another dermal filler currently available in the
market. It is manufactured by Lea Derm, a subdivision of Corneal Group (Paris, France).
The product was developed by Inamed® (Santa Barbara, CA) and currently is distributed by
Allergan Inc. (Irvine, CA, US). It is a non-animal stabilized HA containing high crosslinked
HA made by Streptococcus equi bacteria. Six different formulations of Juvéderm™ have
been developed with concentrations ranging from 18 mg/g to 30 mg/g. These are known to
be highly viscous dermal fillers. The HA is crosslinked (6%) with a patented single-phase
BDDE chemistry, phosphate buffered to 6.5–7.3 pH [140]. The higher HA concentration
and greater crosslinking supports the notion that treatment via Juvéderm™ can last between
6 to 12 months [136].
The main differences between these dermal fillers are the source of HA, concentration,
particle size of beads (if included in the formulation), degree and type of crosslinking, and
inclusion or lack of anesthetic. For the available dermal fillers, the source of HA are either
avian (found primarily in rooster combs) or bacteria (mostly from the synthetic fermentation
of the Staphylococcus equine bacterium). The concentration of HA has an important role in
dermal fillers. Dermal fillers with high HA concentration tend to have better `volume' and
longer duration of effect; however, their high viscosity can be an issue when injecting using
fine needles. In all HA fillers, a single ether crosslink was typically utilized. Recently, HA
fillers have utilized greater degrees of crosslinking. Crosslinking can potentially improve
resistance to degradation, making for a longer lasting treatment, but increasing the difficultly
of injection [3].
Current HA-based dermal fillers have maximum treatment duration up to 12 months (Table
3). To extend this treatment duration, HA with higher molecular weight or more crosslinking
can be used, however injectability of the HA solution drops by increasing HA molecular
weight and corsslinking. This makes the dermal filler difficult to administer, possibly
producing pain for the patient. Therefore, the development of dermal filler products with
enhanced injectability and longer duration is desired.
7.3. Application of hyaluronic acid in osteoarthritis treatment
Osteoarthritis (OA) is the most common disease associated with aging, affecting many
people with about 70% of these individuals aged 65 and over. OA is characterized by the
slow degradation of cartilage, pain, and increasing disability. The disease can have an
impact on several aspects of a patient's life, including functional and social activities [141,
142]. Current pharmacological therapies target palliation of pain and include analgesics (i.e.
acetaminophen, cyclooxygenase-2-specific inhibitors, non-steroidal anti-inflammatory
drugs, tramadol, opioids), intra-articular therapies (glucocorticoids and hyaluronan), and
topical treatments (i.e. capsaicin, methylsalicylate). If none of these therapies work, surgical
joint replacement is the last option, which is costly and highly invasive [142].
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Synovial spaces are the cavities of the joints that facilitate movement of adjacent bones.
Synovial spaces are formed by a surface of cartilage, synovium, and synovial fluid. The
synovial fluid is a clear, colorless or sometimes yellowish liquid secreted into the joint
cavity by the synovioum. The synovial fluid volume is approximately 2 mL in normal
human knee joints and contains electrolytes, low molecular weight organic molecules, and
macromolecules such as glycosaminoglycans (GAGs). GAGs present in the synovial fluid
are chondrotin-4-sulfate (2%), with the remaining 98% made up of HA [141].
The mechanical function of the synovial fluid can be attributed to its rheological properties,
more specifically its viscoelastic properties. Synovial fluid viscoelasticity depends on HA
concentration, molecular weight, and molecular weight distribution, and on the physical and
non-covalent interactions within the HA molecule as well as with other molecules such as
proteins and ions [5]. HA molecules overlap and interact though physical entanglement or
temporary interactions with ions and proteins at physiological conditions. These
interactions, which are dependent on HA molecular weight and concentration, determine the
formation of the transient network structure that is responsible for the viscoelasticity of
synovial fluid [141, 142]. In OA, HA loses these functionalities as a result of reduced HA
molecular weight and concentration; thus, decreasing the viscoelastic properties of synovial
fluid [95, 141, 143].
The viscoelastic behavior of synovial fluid can be described by the elastic modulus (G″) and
viscous modulus (G″) as a function of frequency [94, 95, 144]. The degradation of synovial
fluid is evident from its rheological properties. Generally, aging is the main reason for a
reduction in HA molecular weight or HA concentration (Table 4). After damage or aging,
synovial fluid cannot provide the required viscoelastic response to compression and
tangential forces arising in everyday life, allowing cartilage-cartilage contact and increasing
wear of the joint surface [141, 142]. Intra-articular treatment with HA and hylans
(uncrosslinked HA and crosslinked HA, respectively) has recently been accepted as a
common therapy for reducing pain associated with OA [141, 142]. Currently, products such
as Hyalgan® (HA), Orthovisc® (HA) and Synvisc® (hylan GF 20) are available as
viscosupplements for intra-synovial injection in osteoarthritis treatment (Table 5) [141, 144–
146].
In the 1970s, the first studies on the application of HA for human knee OA were performed
by Rydell and Balasz (1971) and Peyron and Balasz (1974). In 1974, Peyron injected
different volumes of HA into 23 knees and obtained positive results; reducing pain and
increasing patient function. Since then, many HA viscosupplements have been made from
different sources of HA including rooster combs (Table 5). Similar to dermal fillers,
increasing HA concentration and the degree of crosslinking can enhance the performance
viscosupplements for OA treatment; however, the high viscosity of these modified products
may cause difficulties during administration [97]. In 1997, the FDA approved HA
viscosupplementation for OA treatment. Currently, several viscosupplements including
Hyalgan®, Supartz®, Orthovisc®, Synvisc®, and Euflexxa® are available on the market.
Each of these products differ in their method of production, molecular weight, dosing
instructions, and possibly clinical outcomes [147].
Several clinical trials have demonstrated the efficacy and tolerability of intraarticular HA for
the treatment of pain associated with OA. These studies have shown three injections of
Synvisc® (crosslinked HA) can provide relief of knee pain up to 6 months. A competing
product, Hyalgan® (sodium hyaluronate solution), requires 6 injections to reach the same
efficacy of Synvisc® [97, 145, 148, 149]. While Synvisc® was shown to be more efficient
in reducing pain, its structure (high molecular weight HA due to crosslinking) increases the
force required to inject (Table 6). Unlike Synvisc®, Hyalgan® has a lower viscosity,
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making injection easier, but Hyalgan® is not as effective as Synvisc® due to lower
viscoelastic properties (elastic and viscous moduli) [144, 145, 149]. Moreover, Orthovisc®,
one of the viscosupplements with the highest HA concentration, has lower viscosity than
Synvisc® but it is not reported to be as effective as Synvisc® [144, 145, 149]. This creates a
need for development of products with enhanced injectability and yet reasonable viscoelastic
behavior (Synvisc® elastic and viscous moduli values) for osteoarthritis treatment.
8. Conclusion
Hyaluronic acid is a naturally occurring biomolecule abundantly available in body tissues
and fluids. Due to the prevalence of hyaluronic acid in the body and its desirable properties,
HA has been utilized in several types of biomedical products. This article reviewed the
physical and chemical characteristics of HA as applied to tissue engineering, dermal filling,
and viscosupplementation. In each application, difficulties such as potential toxicity of
crosslinking techniques, high viscosity of HA solutions, and rapid elimination have been
raised as limitations to improve biomedical products derived from HA. To overcome these
limitations, current and emerging strategies to modify HA were reviewed as potential
approaches.
Other biomedical applications of HA are also emerging (e.g. drug conjugation and delivery,
therapeutic and/or immune modulation effects, etc.). New chemical modifications performed
on HA are also appearing in the literature. In particular, new strategies for safely
crosslinking HA in situ represent an important paradigm for generating new strategies for
tissue engineering and viscosupplementation. Formulations that improve product
performance will also utilize physical interactions between components (e.g. interactions
between HA nanoparticles). Utilizing particle/polymer or particle/particle interactions may
provide new approaches to tune the viscoelastic properties of HA formulations as applied to
tissue engineering, dermal filling, and osteoarthritis treatment.
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Chemical structure of hyaluronic acid (HA), which is made of disaccharide repeats of N-
acetylglucosamine and glucuronic acid.
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HA catabolic pathway in the body. Arrows show the flow of HA. Concentration (c), half-life
(t1/2), and molecular weight (Mw) of HA within the organ systems are indicated. Figure was
regenerated with permission [2]. High Mw > ~1000 kDa and low Mw < ~450 kDa.
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Table (1)
Examples of body tissues/fluids that contain HA. Table was regenerated with permission [92].
Tissue or body fluid Concentration (μg/g; μg/mL) Remarks
Umbilical cord 4100 High molecular weight HA.
Joint (synovial) fluid 1400–3600 Decreasing HA concentration occurs due to increasing the synovial fluid volumeunder inflammatory conditions.
Vitreous body 140–500 During tissue maturation, HA concentration increases.
Cartilage - HA works as a scaffold for binding other matrix molecules such as aggrecan.
Dermis 200–500 HA is used as a “rejuvenating” agent in cosmetic dermatology.
Epidermis 100 High HA concentration was observed around cells that synthesized dermis.
Thoracic lymph 0.2–50 HA molecular weight affects inflammatory response and cell binding.













Fakhari and Berkland Page 25
Table (2)
Treatments proposed to enhance age-related changes in skin quality [131].
Treatment Remarks
Skin protections and skin
cares
Sunscreens help to diminish changes in skin quality and appearance caused by sun exposure. Daily skin
care is recommended to improve the quality and appearance of aged skin.
Chemical peels Chemical peels applied directly to the skin use alpha-hydroxy acid, salicylic acid, trichloroacetic acid, orphenol can improve the appearance of aged skin.
Nonablative therapies
In nonablative therapies, light or thermal energy from various sources (visible and infrared lasers, intense
pulsed light, light-emitting diodes, and radiofrequency) are used to improve skin texture, discoloration, and
scarring.
Ablative therapies Ablative therapies are laser treatments in which the laser induces ablation of water-containing tissue(epidermal tissue).
Botulinum toxin type A Local injection of botulinum toxin causes temporary muscle denervation, resulting in relaxation ofhyperfunctional facial muscles and smoothing of the skin overlying these muscles.
Dermal fillers Dermal fillers are used to recover soft-tissue volume of the skin and remove skin wrinkles.
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Table (3)
Different types of dermal fillers and some of the commercially available products [3,131, 133, 137].
Material Brand name Description Duration Biodegradability
Autologous fat Viable Fat - Temporary Biodegradable
Hyaluronic acid
Restylene® Crosslinked HA (20 mg/mL) Temporary 6–12 months
Biodegradable
Prelane® Crosslinked HA (20 mg/mL) Temporary 6–12 months
Juvéderm™ Crosslinked HA (24 mg/mL) Temporary up to 12 months
Elevess® Crosslinked HA (28 mg/mL) Temporary months
Hylaform® Crosslinked HA (5 mg/mL) Temporary 3–6 months
Collagen
Zyderm® 3.5% bovine collagen+0.3%lidocaine Temporary 3–4 months
Biodegradable
Zyplast® 3.5% crosslinked bovinecollagen+0.3% lidocaine Temporary 3–6 months
CosmoDerm® 3.5% human collagen+0.3%lidocaine Temporary 3–5 months
CosmoPlast® 3.5% crosslinked humancollagen+0.3% lidocaine Temporary 3–5 months
ArteFill®
20% PMMA microspheres
+80% bovine collagen (3.5%)
+0.3% lidocaine
Permanent Not biodegradable





Semipermanent 18–24 months Biodegradable
β-tricalcium phosphate with
hyaluronic acid Atlean® - Semipermanent Biodegradable
Polyacrylamide gel
Aquamid®









Dimenthylsiloxane polymers Silicone - Permanent Not biodegradable
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Table (4)
Properties of healthy synovial fluid and osteoarthritic synovial fluid [105, 144, 145, 150].
HA molecular







(Pa) at 2.5 Hz
Viscous
modulus (G”)
(Pa) at 2.5 Hz
Healthy Young Synovial Fluid 6.3–7.6 2.5–4 23 7 6–175
Osteoarthritic Synovial Fluid 1.6–3.48 1–2 7 5 0.01–1
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Table (5)
Some of the HA viscosupplements available in the North American market. [141, 144–147]. Adapted data
from reference [146] were used with permission.






acid, 2%) 1000 1 injection 3 Knee or hip, mild or moderate
Fermathron® (Sodium
hyaluronate, 1%) 1000 3–5 injections 2 Knee, mild or moderate
Hyalgan® (Sodium
hyaluronate, 1%) 500–730 3–5 injections 2 Knee, shoulder, or hip
NeoVisc® (Sodium
hyaluronate, 1%) 1000 3–5 injections 2
Synovial fluid replacement following
arthrocentesis
Orthovisc® (Sodium
hyaluronate, 1.4%) 1000–2900 3 injections 2 Knee
Ostenil® (Sodium
hyaluronate, 1%) 1000–2000 3 injections 2
Degenerative or traumatic synovial
joint disorders, including knee joint
Supartz® (Sodium
hyaluronate, 1%) 620–1170 3–5 injections 2.5
Knee nonresponsive to conservative
therapy
Suplasyn® (Sodium
hyaluronate, 1%) 500–730 3–6 injections 2
Synovial fluid replacement following
arthrocentesis
Synvisc® (Hylan G-F 20;
Crosslinked HA) 6000–7000 3 injections 2
Knee nonresponsive to 0.8%
conservative therapy
*
The number of weekly intra-articular injections per treatment course, excluding Durolane®, which is given as a single injection.
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Table (6)
Properties of Hyalgan® and Synvisc®. Data were adapted from Hyalgan® product information, Orthovisc®
product information, Synvisc® product information, and references [105, 144, 145].
Brand name Molecular weight (kDa)
Viscoelastic properties
Number of injections Duration ofpain relief
Elastic
modulus (G')
(Pa) at 2.5 Hz
Viscous
modulus (G”)
(Pa) at 2.5 Hz
Hyalgan® (Uncrosslinked) 500–730 0.6 3 3–5 6 months
Orthovisc® (Uncrosslinked) 1000–2900 60 46 3 6 months
Synvisc® (Crosslinked polymer) 6000–7000 111± 13 25±2 3 6 months
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